Exxon Mobil Says May Export LNG from the U.S.

Exxon Mobil, the world's largest publicly traded energy company, is considering exporting liquefied natural gas (LNG) from the United States, CEO Rex Tillerson said on Tuesday.

The company has been North America's largest natural gas producer since its 2010 purchase of XTO Energy, helped by a boom in output of shale gas.

Asked whether Exxon Mobil planned to export LNG from the United States, Tillerson said: "We are studying it."

U.S. natural gas prices have hit their lowest in a decade and are expected to remain low for years due in large part to ramped up production from shale reserves.

Tillerson confirmed the company was looking at building the new petrochemical plant in Texas to take advantage of cheap shale gas, but said it had not decided on the level of investment nor whether it would export petrochemicals.

"We will see where the markets are for those chemicals," he said, speaking at the World Gas Conference in the Malaysian capital.

The plant could be online as soon as 2016, according to a U.S. environmental filing seen by Reuters.

It would sharply crank up Exxon Mobil's chemical production capacity and help it compete more effectively with rival Dow Chemical, the largest U.S. chemical maker.

 

 

 

 

 

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.